Arcadia Biosciences (NASDAQ:RKDA) Sees Unusually-High Trading Volume

Arcadia Biosciences Inc (NASDAQ:RKDA) saw an uptick in trading volume on Wednesday . 1,000,044 shares changed hands during mid-day trading, an increase of 84% from the previous session’s volume of 544,451 shares.The stock last traded at $5.91 and had previously closed at $4.91.

A number of brokerages have recently weighed in on RKDA. Zacks Investment Research upgraded Arcadia Biosciences from a “hold” rating to a “buy” rating and set a $5.00 price target for the company in a research report on Thursday, February 14th. National Securities restated a “buy” rating and issued a $15.00 price target on shares of Arcadia Biosciences in a research report on Thursday, May 9th. Finally, HC Wainwright restated a “buy” rating and issued a $14.00 price target (down previously from $20.00) on shares of Arcadia Biosciences in a research report on Thursday, June 6th.

The stock has a market capitalization of $28.24 million, a P/E ratio of -0.70 and a beta of -1.68. The company has a quick ratio of 6.19, a current ratio of 6.26 and a debt-to-equity ratio of 2.80.

Arcadia Biosciences (NASDAQ:RKDA) last posted its quarterly earnings data on Wednesday, May 8th. The basic materials company reported ($1.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.63). The company had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $0.40 million. Arcadia Biosciences had a negative return on equity of 178.78% and a negative net margin of 1,099.22%. As a group, analysts expect that Arcadia Biosciences Inc will post -4.62 earnings per share for the current year.

An institutional investor recently bought a new position in Arcadia Biosciences stock. Vanguard Group Inc acquired a new position in shares of Arcadia Biosciences Inc (NASDAQ:RKDA) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 18,655 shares of the basic materials company’s stock, valued at approximately $91,000. Vanguard Group Inc owned approximately 0.39% of Arcadia Biosciences at the end of the most recent quarter. 4.04% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This news story was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://sportsperspectives.com/2019/06/14/arcadia-biosciences-nasdaqrkda-sees-unusually-high-trading-volume.html.

Arcadia Biosciences Company Profile (NASDAQ:RKDA)

Arcadia Biosciences, Inc, an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits.

See Also: Exchange-Traded Funds (ETFs)

Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.